Novo Nordisk - Regulatory Approval (December 2025): FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill-which launched in January 2026 [3]
CoQ10: Works alongside glutathione to protect the heart and energy-producing centers of the cells
Tuttle, MD, FACP, FASN, FNKF, University of Washington, who summarized the main findings of the FLOW trial and the potential clinical implications
SURMOUNT-1 (N=2,539) demonstrated 20.9% mean body weight reduction at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo
Nutritional Deficiency as a Secondary Risk Factor While weight loss itself triggers telogen effluvium, inadequate protein, iron, zinc, or B-vitamin intake accelerates and prolongs hair shedding
In studies, most people lose weight, but the amount and speed vary a lot from person to person